Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 21, 2020
Daily News
August 21, 2020
- Japan Plans to Provide Indemnity to Coronavirus Vaccine Suppliers
August 21, 2020
- Fabricated Data Found in 5 Papers by Ex-NCVC/Osaka Univ. Doctor; 1 Used to Design JANP Study
August 21, 2020
- No New Concerns Found for Veklury’s Safety, Efficacy at This Point: MHLW Official
August 21, 2020
- Fujifilm’s Avigan COVID-19 Data Won’t Be Fully Ready until 1 Month from Now
August 21, 2020
- BMS Introduces New Corporate Brand in Japan
August 21, 2020
- Viltepso Now Available in US: Nippon Shinyaku
August 21, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…